Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash declines year over year

Q1 FY2026 net change in cash of $6.5M (cash outflow) fell 79.8% year over year, ahead of the -179.8% change in trailing-twelve-month net change in cash. Sequentially, it fell 64.4% from the prior quarter. Over 3 fiscal years it compounded at +127.8% a year.

Context

  • Net change in cash amounted to 3125.0% of revenue in FY2025, up 2775.5 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -79.8% holds above the trailing-twelve-month pace of -179.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.5M-64.4% QoQ
Last fiscal yearDec 2025
-$87.41M-164.3% YoY
LTMMar 2026
-$61.73M-179.8% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-79.8%——
1 year-164.3%——
3-year CAGR+127.8%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(87.41M) USD
Year-over-year change
-164.3%

Net Change in Cash vs competitors

How RNAC compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -179.8% is the 7th highest of 9, against a peer median of +125.4%.
  • Net change in cash amounts to 3477.6% of revenue for RNAC, versus a peer median of 96.6%.
RNAC Competitors
Net Change in Cash for RNAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$100M USD-769.9%+42.0%169491.5%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$61.73M USD-179.8%+127.8%3477.6%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$35.93M USD+89.5%+8.8%—
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$18.61M USD-347.9%-40.1%—
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$17.5M USD+161.4%+56.0%34.3%
IVAInventiva S.A.FY2025€14.17M EUR-79.7%+326.2%316.0%
MDWDMediWound Ltd.LTM Mar 2026$13.99M USD+520.6%—96.6%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$11.75M USD+1066.8%+102.1%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$10.02M USD+301.3%+8.1%30.6%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$4.8M USD———
Peer median (excluding RNAC) —+125.4%+42.0%96.6%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Depreciation & Amortization1.25M1.29M843K1.15M2.96M
Deferred Income Tax2.4M(21.4M)(19M)287K(9.19M)
Stock-Based Compensation7.72M11.19M22.52M6.58M10.52M
Change in Working Capital(48.19M)(60.38M)4.97M(5.79M)(8.06M)
Accounts Receivables(2.69M)3.32M907K7.98M(243K)
Inventory211K920K000
Accounts Payables(219K)92K2.83M(2.93M)1.07M
Other Working Capital(45.5M)(64.71M)1.23M(10.84M)(8.89M)
Other Non-Cash Items2.13M2.29M159.21M51.52M60.14M
Operating Cash Flow(60.38M)(31.63M)(51.16M)(23.67M)(73.94M)
Capital Expenditures(1.09M)(1.2M)(206K)(9.09M)(5.45M)
Acquisitions (Net)006.56M351K0
Purchases of Investments(32.46M)(33.5M)000
Sales of Investments16.4M19.7M28.25M00
Other Investing Activities00000
Investing Cash Flow(17.14M)(15M)34.61M(8.74M)(5.45M)
Debt Repayment00(27.46M)00
Common Stock Issued51.96M38.98M0124.44M(301K)
Common Stock Repurchased00(6.17M)00
Dividends Paid00000
Other Financing Activities939K235K231K3.99M(7.75M)
Financing Cash Flow52.9M39.22M(13.15M)168.43M(8.06M)
Effect of Forex Changes(3K)20K(53K)(21K)45K
Net Change in Cash(24.63M)(7.4M)(29.75M)135.99M(87.41M)
Free Cash Flow(61.47M)(32.83M)(51.37M)(32.77M)(79.4M)

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.